440105-91-9

Upstream product

• 62803-47-8 6-hydroxy-1-indanone 
• 58479-61-1 tert-butylchlorodiphenylsilane 

Downstream Products

• 1435276-12-2 (1H-inden-5-yloxy)(tert-butyl)diphenylsilane 
• 1435276-18-8 C₂₉H₃₂O₃Si 
• 1222092-17-2 C₃₅H₃₇FO₄ 
• 1222092-18-3 C₃₅H₃₇FO₄ 
• 1222092-19-4 C₃₅H₃₇FO₄ 
• 1222092-20-7 C₃₅H₃₇FO₄ 
• 1448668-63-0 C₃₅H₃₉FO₄ 
• 1222088-92-7 (1R,2R)-6'-((2-((S)-2,2-dimethylcyclopentyl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methoxy)-2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-carboxylic acid 
• 1222088-90-5 AM-5262 
• 1222088-82-5 (1R,2R)-6'-((2-(5,5-dimethylcyclopent-1-en-1-yl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methoxy)-2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-carboxylic acid 
• 1222088-83-6 (1S,2S)-6'-((2-(5,5-dimethylcyclopent-1-en-1-yl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methoxy)-2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-carboxylic acid 
• 1222088-84-7 (1R,2S)-6'-((2-(5,5-dimethylcyclopent-1-en-1-yl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methoxy)-2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-carboxylic acid 
• 1222088-85-8 (1S,2R)-6'-((2-(5,5-dimethylcyclopent-1-en-1-yl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methoxy)-2',3'-dihydrospiro[cyclopropane-1,1'-indene]-2-carboxylic acid 
• 1435274-47-7 (1S,1aS,6aR)-3-((2-(5,5-dimethylcyclopent-1-en-1-yl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methoxy)-1,1a,6,6a-tetrahydrocyclopropa[a]indene-1-carboxylic acid 

Relevant academic research and scientific papers

Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles

GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist of GPR40. In this repor

SPIROCYCLIC GPR40 MODULATORS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I'B, where the definitions of the variables are provided herein. The present invention also

3-Aminopyrrolidinone farnesyltransferase inhibitors: Design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency

A series of macrocyclic 3-aminopyrrolidinone farnesyltransferase inhibitors (FTIs) has been synthesized. Compared with previously described linear 3-aminopyrrolidinone FTIs such as compound 1, macrocycles such as 49 combined improved pharmacokinetic prope